Navigation Links
CetylMax(R) and Flexadren(R) Win Federal Lawsuit - Court Rules Against Imagenetix
Date:6/22/2009

SAN DIEGO, June 22 /PRNewswire/ -- CetylMax, LLC and Flexadren, LLC, manufacturers and distributors of tablet form and topical Cetylated Fatty Acids (CFA's) products aiding in joint support and pain relief, announced today that Imagenetix (OTC Bulletin Board: IAGX), the manufacturer of Celadrin, did not prevail in its claims against CetylMax(R) and Flexadren(R), and misrepresented the nature and outcome of the Federal litigation between CetylMax(R) and Flexadren(R) and Imagenetix.

Imagenetix filed a Federal lawsuit against CetylMax(R) and Flexadren(R) on July 29, 2008 ("the Imagenetix lawsuit"), in the United States District Court for the Southern District of California. The Imagenetix lawsuit claimed that CetylMax(R) and Flexadren(R) had affronted the Lanham Act and California Business and Professions Code. CetylMax(R) and Flexadren(R) vehemently denied the Imagenetix lawsuit assertions, and immediately filed their own counterclaim lawsuit against Imagenetix ("the CetylMax/Flexadren lawsuit") in the same court.

On October 27, 2008, the parties appeared before the Honorable Judge William McCurine, Jr., for an Early Neutral Evaluation Conference (ENE). At that conference the parties mutually settled all of their respective claims, raised in both the Imagenetix lawsuit and the CetylMax/Flexadren lawsuit. The sole issue left for the Court to decide was whether any attorneys' fees should be awarded.

Following briefing by the parties' attorneys, on February 2, 2009, Judge McCurine ruled that Imagenetix was not entitled to any attorneys' fees. The Court concluded that Imagenetix had not succeeded on any of its claims against CetylMax(R) or Flexadren(R), and was thus not the prevailing party. Judge McCurine's decision cleared CetylMax(R) and Flexadren(R) of any bad faith or malice.

Roger LeFevre, Chief Executive Officer of CetylMax and Flexadren, commented, "both CetylMax(R) and Flexadren(R) have been completely exonerated of all Imagenetix's claims, and we're very happy with the Court's decision."

About Cetylated Fatty Acids or CFA's -

Cetylated Fatty Acids or CFA's are rooted in a health compound(s) derived through a process of "esterifying" fatty acids. The origin of CFA's can be traced to discoveries made and processes developed by Dr. Harry W. Diehl, Ph.D., including Cetyl Myristoleate or the cetyl ester of Myristoleic Acid. CFA's are all-natural and have been clinically demonstrated to help support, and indeed restore joint health and flexibility. CFA's are marketed under various brand names, including CetylMax(R) and Flexadren(R). There have been many studies performed on and scientific presentations made relating to CFA's. Published scholarly articles have described the systemic enhancement and lubricating properties of CFA's to cell membranes throughout the body, providing youthful cell fluidity and elasticity. Some of the benefits of CFA's include the enhancement of joint fluids that cushion bones and joints ¿ to maintain flexibility and mobility, so that an individual can move with greater ease and range-of-motion. CFA's have been proven to provide cumulative (continuous and restorative) benefits.

About CetylMax(R) and Flexadren(R) --

CetylMax(R) and Flexadren(R) product lines consist of both tablet form and topical over-the-counter (OTC) joint support supplements (also known as nutraceuticals) available directly to consumers through the Internet at www.cetylmax.com and www.flexadren.com. Both products are manufactured under FDA guidelines using the highest quality formulations of Cetylated Fatty Acids or CFA's and Glucosamine. Among other positive benefits, CetylMax(R) and Flexadren(R) aid in restoring soft tissue within and lubrication of joints throughout the body, which helps ease inflammation and the pain caused by inflammation.*

CetylMax(R) and Flexadren(R) are part of the Optimal Health Science(R) www.optimalhealthscience.com family of anti-aging products.

* These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.


'/>"/>
SOURCE Optimal Health Science
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pennsylvania Department of Health Applauds New Federal Anti-Tobacco Law
2. LA County Calls for Repeal of Federal Cell Tower Health Preemption
3. Ted Karkus and Karkus Slate of Directors Prevail in Federal Court, Seated as Directors of The Quigley Corporation; Ted Karkus Elected Chairman of the Board
4. BioFit Intensive Plus™ Chairs Meet Federal Standard for Continuous Intensive Use
5. Medical, Insurance, Automotive and Safety Groups Call on Congress to Make This the "Last Deadly Summer for Teens" by Swiftly Passing Federal Teen Driving Safety Bill
6. Community Businesses Impacted by Looming Cuts to Long Term Care Federal Funding
7. New CASA* Report Finds Federal, State and Local Governments Spend Almost Half a Trillion Dollars a Year on Substance Abuse and Addiction
8. Prop. 8 Challenged in Federal Court; Ted Olson & David Boies to Argue Case
9. New report on federal family planning program
10. QLT Announces Court Response to Motion to Dismiss and Removal of Case to Federal Court
11. American Association for Homecare Supports Expanded Federal Efforts by DOJ and HHS to Combat Medicare Fraud
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Worth, TX (PRWEB) , ... October 13, 2017 ... ... financial planning agency serving communities in the greater Dallas, Miami, and Raleigh regions, ... young boy fighting to overcome a rare and deadly chromosome abnormality. , After ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... established the certification process to promote standards of excellence for the field of ... scheduled for March 22 – 25, 2018 in Orlando, Florida at the Omni ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that ... insurance companies have a waiver for care if the client has a cognitive impairment ... family pays for care, is often waived, so the benefits from their insurance start ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest Obamacare ... Bill Cassidy (R-LA) and Lindsey Graham ... that the medical device industry is in an odd ... tax, the 2.3% excise tax on medical device sales ... also want covered patients, increased visits and hospital customers ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a ... targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , ...
Breaking Medicine Technology: